A Phase 1 Dose Escalation Study of TKM, a RNAi Therapeutic Directed Against PLK1, in Patients With Advanced Solid Tumors - PLK1 - Document - PDFSEARCH.IO

First Page	Meta Content
	A Phase 1 Dose Escalation Study of TKM, a RNAi Therapeutic Directed Against PLK1, in Patients With Advanced Solid Tumors Add to Reading List Open Document File Size: 744,62 KB Share Result on Facebook

A Phase 1 Dose Escalation Study of TKM, a RNAi Therapeutic Directed Against PLK1, in Patients With Advanced Solid TumorsAdd to Reading List